Is UTMD a good stock to buy right now?

Based on our 6-factor quantitative model, UTAH MEDICAL PRODUCTS INC (UTMD) receives a "Hold" rating with a composite score of 49.8/100. It is ranked #1,262 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 63/100, Momentum 51/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for UTMD?

UTAH MEDICAL PRODUCTS INC (UTMD) has a "Hold" rating and 3-star score. The composite score of 49.8 ranks it #1,262 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is UTMD in?

UTAH MEDICAL PRODUCTS INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $200 million. It is classified as a micro-cap stock.

Does UTMD pay a dividend?

Yes, UTMD pays a dividend with a current yield of 2.13%. For every $1,000 invested, you would receive approximately $21.30 in annual dividend income.

What is UTMD's P/E ratio?

UTMD has a trailing P/E ratio of 16.46x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is UTMD?

UTMD's quality factor score is 50/100. Gross margin: 57.1%. ROE: 10.3% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is UTMD valued compared to peers?

UTMD's value factor score is 63/100 (higher = cheaper). Key multiples: P/E 16.5x, EV/EBITDA 16.4x. The stock appears attractively valued versus peers.

What is UTMD's debt level?

UTMD's debt-to-equity ratio is 0%. Sector average: 32%. Low leverage suggests conservative financial management.

UTMD has a beta of 0.35, meaning it is less volatile than the market. Stability score: 87/100.

Does UTMD have high short interest?

UTMD's short interest factor score is 4/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

UTMD Stock Analysis: Top Micro-Cap Hold (Score 49.8/100) | Blank Capital Research

Pro Equity Research

UTMD: A Debt-Free Fortress in Women's Healthcare

Blank Capital Research Team

•March 26, 2026

Executive Summary

Utah Medical Products, Inc. (UTMD) manufactures a wide range of specialized medical devices for the women's healthcare, neonatal, and intensive care markets.

Investment Thesis

Utah Medical is a masterclass in conservative management and high-margin niche dominance. The company focuses on essential, low-tech medical consumables (like fetal monitors and specialized catheters) that have extremely long product lifecycles and near-zero competition from major med-tech firms. Their defining characteristic is an almost unbelievable level of financial discipline: UTMD has zero debt and has historically operated with EBITDA margins in the high 30s. They don't chase expensive acquisitions or vanity growth; instead, they focus on hyper-efficient manufacturing and returning almost all of their cash to shareholders via dividends and buybacks. It is a medical device 'utility' at a value price.

Key Growth Drivers

Non-Discretionary Product Moat

Utah Medical's products are essential for high-stakes neonatal and labor & delivery care, ensuring stable demand regardless of the economic cycle.

Zero-Debt Financial Posture

With a massive cash pile and no debt, UTMD is virtually bulletproof and offers ultimate downside protection for conservative investors.

Elite Operating Efficiency

Management's focus on cost control and lean manufacturing results in profitability metrics that dwarf much larger medical device companies.

Valuation & Financial Modeling

UTMD trades at an attractive multiple when you adjust for its excess cash. While it is not a 'growth' story, it is one of the safest and most reliable cash-generating assets in the healthcare sector. It is a quintessential value stock.

Risk Factors & Bear Case

The primary risk is the low organic growth rate; the company prioritizes profitability over raw volume expansion. Additionally, as a micro-cap firm, liquidity in the stock is low.

Conclusion

Utah Medical Products is an essential holding for defensive value portfolios. It offers unmatched safety and a high-yield dividend backed by critical medical infrastructure. Rated 'Buy'.

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
UTMD	+1.60%	+4.40%	+3.32%	+17.76%	+24.57%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+1.67%	+0.80%	+2.99%	+18.12%	-4.95%	-	-	-
Alpha vs Sector	+2.96%	+4.06%	+7.14%	+22.60%	+15.37%	-	-	-

Metric	UTMD	Benchmark
P/E Ratio	16.5x	-30%
EV/EBITDA	16.4x	+159%
Price / Book	1.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
UTMD UTAH MEDICAL PRODUCTS INC	50	50	63	51	16.5x	10.3%	57.1%	31.1%	-5.7%	0.0x	$200M
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%
Operating Margin %	0.3%	0.3%	0.3%	0.3%	0.4%	0.4%	0.3%	0.4%	0.4%	0.5%	0.4%
EBITDA Margin %	0.3%	0.3%	0.3%	0.3%	0.4%	0.4%	0.5%	0.5%	0.5%	0.5%	0.5%
Net Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.4%	0.2%	0.3%
FCF Margin %	-	-	-	-	-	-	45.7%	35.2%	39.1%	37.0%	28.6%
ROE %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	0.2%
ROA %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	0.2%
ROIC %	0.1%	7.6%	9.1%	10.3%	13.7%	13.9%	21.0%	23.9%	39.0%	39.3%	29.8%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

Operating Margin %

0.3%

0.4%

0.3%

0.4%

0.5%

0.4%

EBITDA Margin %

0.3%

0.4%

0.5%

Net Margin %

0.3%

0.4%

0.2%

0.3%

FCF Margin %

45.7%

35.2%

39.1%

37.0%

28.6%

ROE %

0.1%

0.2%

0.1%

0.2%

ROA %

0.1%

0.2%

0.1%

0.2%

ROIC %

0.1%

7.6%

9.1%

10.3%

13.7%

13.9%

21.0%

23.9%

39.0%

39.3%

29.8%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$39M	$39M	$41M	$50M	$52M	$49M	$42M	$47M	$42M	$41M	$39M	$40M
	—	$17M	$17M	$20M	$20M	$18M	—	—	—	—	—	—
	$23M	$22M	$24M	$30M	$32M	$31M	$26M	$29M	$26M	$26M	$24M	$24M
Gross Margin	57.1%	57.1%	59.0%	59.8%	61.6%	63.0%	60.6%	62.8%	62.6%	63.7%	60.3%	60.2%
	—	$668K	$813K	$560K	$493K	$526K	$486K	$483K	$454K	$447K	$475K	$522K
Depreciation	—	—	—	—	—	—	$7M	$7M	$3M	$3M	$3M	$3M
Total Operating Expenses	—	$11M	$11M	$13M	$12M	$12M	—	—	—	—	—	—
	$12M	$11M	$14M	$17M	$20M	$19M	$14M	$18M	$19M	$19M	$16M	$16M
EBIT	$12M	$11M	$14M	$17M	$20M	$19M	$14M	$18M	$19M	$19M	$16M	$16M
EBITDA	$12M	$11M	$14M	$17M	$20M	$19M	$21M	$25M	$22M	$22M	$19M	$19M
Operating Margin	31.1%	29.6%	33.2%	33.4%	37.9%	38.5%	32.5%	37.6%	44.5%	45.9%	41.2%	39.0%
EBITDA Margin	31.2%	29.6%	33.2%	33.4%	37.9%	38.5%	49.6%	52.2%	52.6%	52.5%	48.7%	46.5%
	—	—	—	—	—	—	—	—	—	—	—	$65K
	—	$14M	$17M	$20M	$21M	$19M	—	—	—	—	—	—
Income Tax Expense	—	$3M	$3M	$3M	$4M	$4M	$3M	$3M	$904K	$11M	$4M	$4M
	$12M	$11M	$14M	$17M	$16M	$15M	$11M	$15M	$19M	$9M	$12M	$12M
Net Margin	31.1%	29.3%	33.9%	33.1%	31.5%	30.1%	25.6%	31.4%	44.2%	20.5%	30.9%	29.5%
	$3.48	$3.48	$3.96	$4.58	$4.53	$4.05	$2.95	$3.96	$4.97	$2.29	$3.23	$3.16
Diluted EPS	$3.48	$3.48	$3.96	$4.57	$4.52	$4.04	$2.95	$3.96	$4.97	$2.29	$3.23	$3.16
Weighted Avg Basic	—	3M	4M	4M	4M	4M	—	—	—	—	—	—
Weighted Avg Diluted	—	3M	4M	4M	4M	4M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$39M

$41M

$50M

$52M

$49M

$42M

$47M

$42M

$41M

$39M

$40M

—

$17M

$20M

$18M

—

$23M

$22M

$24M

$30M

$32M

$31M

$26M

$29M

$26M

$24M

Gross Margin

57.1%

59.0%

59.8%

61.6%

63.0%

60.6%

62.8%

62.6%

63.7%

60.3%

60.2%

—

$668K

$813K

$560K

$493K

$526K

$486K

$483K

$454K

$447K

$475K

$522K

Depreciation

—

$7M

$3M

Total Operating Expenses

—

$11M

$13M

$12M

—

$12M

$11M

$14M

$17M

$20M

$19M

$14M

$18M

$19M

$16M

EBIT

$12M

$11M

$14M

$17M

$20M

$19M

$14M

$18M

$19M

$16M

EBITDA

$12M

$11M

$14M

$17M

$20M

$19M

$21M

$25M

$22M

$19M

Operating Margin

31.1%

29.6%

33.2%

33.4%

37.9%

38.5%

32.5%

37.6%

44.5%

45.9%

41.2%

39.0%

EBITDA Margin

31.2%

29.6%

33.2%

33.4%

37.9%

38.5%

49.6%

52.2%

52.6%

52.5%

48.7%

46.5%

—

$65K

—

$14M

$17M

$20M

$21M

$19M

—

Income Tax Expense

—

$3M

$4M

$3M

$904K

$11M

$4M

$12M

$11M

$14M

$17M

$16M

$15M

$11M

$15M

$19M

$9M

$12M

Net Margin

31.1%

29.3%

33.9%

33.1%

31.5%

30.1%

25.6%

31.4%

44.2%

20.5%

30.9%

29.5%

$3.48

$3.96

$4.58

$4.53

$4.05

$2.95

$3.96

$4.97

$2.29

$3.23

$3.16

Diluted EPS

$3.48

$3.96

$4.57

$4.52

$4.04

$2.95

$3.96

$4.97

$2.29

$3.23

$3.16

Weighted Avg Basic

—

Weighted Avg Diluted

—

UTAH MEDICAL PRODUCTS INC (UTMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does UTAH MEDICAL PRODUCTS INC Do?

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah. UTAH MEDICAL PRODUCTS INC (UTMD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kevin L. Cornwell and employs approximately 180 people. With a market capitalization of $200M, UTMD is one of the notable companies in the Healthcare sector.

UTAH MEDICAL PRODUCTS INC (UTMD) Stock Rating — Hold (April 2026)

As of April 2026, UTAH MEDICAL PRODUCTS INC receives a Hold rating with a composite score of 49.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.UTMD ranks #1,262 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, UTAH MEDICAL PRODUCTS INC ranks #96 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

UTMD Stock Price and 52-Week Range

UTAH MEDICAL PRODUCTS INC (UTMD) currently trades at $64.86. The 52-week high for UTMD is $68.71, which means the stock is currently trading -5.6% from its annual peak. The 52-week low is $51.26, putting the stock 26.5% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is UTMD Overvalued or Undervalued? — Valuation Analysis

UTAH MEDICAL PRODUCTS INC (UTMD) carries a value factor score of 63/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 16.46x, compared to the Healthcare sector average of 23.63x — a discount of 30%. The price-to-book ratio stands at 1.69x, versus the sector average of 2.75x. The price-to-sales ratio is 5.12x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, UTMD trades at 16.43x EV/EBITDA, versus 6.34x for the sector.

Overall, UTMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

UTAH MEDICAL PRODUCTS INC Profitability — ROE, Margins, and Quality Score

UTAH MEDICAL PRODUCTS INC (UTMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 10.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 10.0% versus the sector average of -33.1%.

On a margin basis, UTAH MEDICAL PRODUCTS INC reports gross margins of 57.1%, compared to 71.5% for the sector. The operating margin is 31.1% (sector: -66.1%). Net profit margin stands at 31.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -5.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

UTMD Debt, Balance Sheet, and Financial Health

UTAH MEDICAL PRODUCTS INC has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 37.62x, indicating strong short-term liquidity. Total debt on the balance sheet is $0.

UTMD has a beta of 0.35, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for UTAH MEDICAL PRODUCTS INC is 87/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

UTAH MEDICAL PRODUCTS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, UTAH MEDICAL PRODUCTS INC reported revenue of $39M and earnings per share (EPS) of $3.48. Net income for the quarter was $12M. Gross margin was 57.1%. Operating income came in at $12M.

In FY 2025, UTAH MEDICAL PRODUCTS INC reported revenue of $39M and earnings per share (EPS) of $3.48. Net income for the quarter was $11M. Gross margin was 57.1%. Revenue grew -5.8% year-over-year compared to FY 2024. Operating income came in at $11M.

In Q3 2025, UTAH MEDICAL PRODUCTS INC reported revenue of $10M and earnings per share (EPS) of $0.82. Net income for the quarter was $3M. Gross margin was 57.1%. Revenue grew -1.9% year-over-year compared to Q3 2024. Operating income came in at $3M.

In Q2 2025, UTAH MEDICAL PRODUCTS INC reported revenue of $10M and earnings per share (EPS) of $0.94. Net income for the quarter was $3M. Gross margin was 56.2%. Revenue grew -4.3% year-over-year compared to Q2 2024. Operating income came in at $3M.

Over the past 8 quarters, UTAH MEDICAL PRODUCTS INC has demonstrated a growth trajectory, with revenue expanding from $10M to $39M. Investors analyzing UTMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

UTMD Dividend Yield and Income Analysis

UTAH MEDICAL PRODUCTS INC (UTMD) currently pays a dividend yield of 2.1%. At this yield, a $10,000 investment in UTMD stock would generate approximately $$213.00 in annual dividend income. With a net margin of 31.1%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.

UTMD Momentum and Technical Analysis Profile

UTAH MEDICAL PRODUCTS INC (UTMD) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

UTMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, UTAH MEDICAL PRODUCTS INC (UTMD) ranks #96 out of 838 stocks based on the Blank Capital composite score. This places UTMD in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing UTMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full UTMD vs S&P 500 (SPY) comparison to assess how UTAH MEDICAL PRODUCTS INC stacks up against the broader market across all factor dimensions.

UTMD Next Earnings Date

No upcoming earnings date has been announced for UTAH MEDICAL PRODUCTS INC (UTMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy UTMD? — Investment Thesis Summary

UTAH MEDICAL PRODUCTS INC presents a balanced picture with arguments on both sides. The value score of 63/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 87/100) reduces downside risk.

In summary, UTAH MEDICAL PRODUCTS INC (UTMD) earns a Hold rating with a composite score of 49.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on UTMD stock.

Related Resources for UTMD Investors

Explore more research and tools: UTMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare UTMD head-to-head with peers: UTMD vs AZN, UTMD vs SLGL, UTMD vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings

Stocks Fall as Crude Oil Jumps on Doubts About a Ceasefire in Iran

Stocks Rebound on Optimism US-Iran Ceasefire to Hold

Iran Ceasefire Skepticism Weighs on Stocks

Stocks Finish Higher on US Push to End Iran War

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

UTAH MEDICAL PRODUCTS INC (UTMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does UTAH MEDICAL PRODUCTS INC Do?

UTAH MEDICAL PRODUCTS INC (UTMD) Stock Rating — Hold (April 2026)

UTMD Stock Price and 52-Week Range

Is UTMD Overvalued or Undervalued? — Valuation Analysis

UTAH MEDICAL PRODUCTS INC Profitability — ROE, Margins, and Quality Score

UTMD Debt, Balance Sheet, and Financial Health

UTAH MEDICAL PRODUCTS INC Revenue and Earnings History — Quarterly Trend

UTMD Dividend Yield and Income Analysis

UTMD Momentum and Technical Analysis Profile

UTMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

UTMD Next Earnings Date

Should You Buy UTMD? — Investment Thesis Summary

Related Resources for UTMD Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Revenue Growth

Gross Margin

Operating Margin

Net Margin

Return on Equity

Return on Assets

Debt/Equity

Dividend Yield

Intelligence Feed

Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings

Stocks Fall as Crude Oil Jumps on Doubts About a Ceasefire in Iran

Stocks Rebound on Optimism US-Iran Ceasefire to Hold

Iran Ceasefire Skepticism Weighs on Stocks

Stocks Finish Higher on US Push to End Iran War